RxDoctor Payments DataLook up a doctor →

Vipin Gupta, MD

Gastroenterology · Lighthouse Point, FLNPI 1912091794

Payments from drug & device makers

$571,085in general payments, 2019–2025

Across 439 payments — averaging $1300.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$291K
  • E.r. Squibb & Sons, L.L.C.$157K
  • Sanofi US Services Inc.$50K
  • Takeda Pharmaceuticals U.S.A., Inc.$23K
  • Bristol Myers Squibb$18K
  • Bausch Health US, LLC$17K
  • plus $14K from 25 others
$5,547in research payments, 2019–2025

Across 12 payments — averaging $462.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$5K
  • Sanofi US Services Inc.$538

What the payments were for

  • Food & beverage$6,672100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$571,085 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$561,072
Medicare patients
1,230
Services billed
5,833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide63$59,324
Mesalamine11$4,127
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl104$1,813
Famotidine153$1,391
Pantoprazole Sodium119$804
Lactulose30$634
Omeprazole51$389
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl18$301
Hydrocortisone18$253
Sucralfate13$170
Metoclopramide Hcl11$50

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$291,301$59,32463 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Lighthouse Point

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →